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Aberrant or modiﬁed splicing patterns of genes are causative for many human diseases. Therefore, the identiﬁcation
of genetic variations that cause changes in the splicing pattern of a gene is important. Elsewhere, we described the
widespread occurrence of alternative splicing at NAGNAG acceptors. Here, we report a genomewide screen for
single-nucleotide polymorphisms (SNPs) that affect such tandem acceptors. From 121 SNPs identiﬁed, we extracted
64 SNPs that most likely affect alternative NAGNAG splicing. We demonstrate that the NAGNAGmotif is necessary
and sufﬁcient for this type of alternative splicing. The evolutionarily young NAGNAG alleles, as determined by
the comparison with the chimpanzee genome, exhibit the same biases toward intron phase 1 and single–amino
acid insertion/deletions that were already observed for all human NAGNAG acceptors. Since 28% of the NAGNAG
SNPs occur in known disease genes, they represent preferable candidates for a more-detailed functional analysis,
especially since the splice relevance for some of the coding SNPs is overlooked. Against the background of a general
lack of methods for identifying splice-relevant SNPs, the presented approach is highly effective in the prediction of
polymorphisms that are causal for variations in alternative splicing.
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SNPs, as the most abundant form of genetic variation,
contribute signiﬁcantly to phenotypic individuality and
disease susceptibility. SNPs are mostly biallelic and are
therefore easy to assay once they are described. Given
their abundance in the human genome (∼1 SNP every
300 bp [Ke et al. 2004]) and their ease of high-through-
put typing, SNPs progressively replace microsatellites as
ﬁrst-choice genetic markers in association and linkage
studies.
Much interest focuses on SNPs that are located in cod-
ing regions, since those SNPs may alter the protein se-
quence. However, SNPs can also inﬂuence splicing, which
usually has a greater effect on the resulting protein than
does the alteration of a single codon. Recently, splicing
mutations have been suspected to be the most frequent
cause of hereditary diseases (Lopez-Bigas et al. 2005).
Accordingly, an increasing number of SNPs have been
described that cause diseases by a change or disruption
of the normal splicing pattern (for review, see Cartegni
et al. [2002] and Garcia-Blanco et al. [2004]). These
splice-relevant SNPs affect donor and acceptor splice sites,
branch points, exonic as well as intronic splicing en-
hancers and silencers or alter important mRNA second-
ary structures. For example, the G allele of the silent
coding SNP rs17612648 in the PTPRC gene that is as-
sociated with multiple sclerosis destroys an exonic splic-
ing silencer and abolishes the skipping of exon 4 (Lynch
and Weiss 2001), and the SNP rs2076530 in BTLN2
that is associated with sarcoidosis leads to the activation
of a cryptic donor site and a cryptic donor splice site 4
nt upstream (Valentonyte et al. 2005). Since the impact
of SNPs on splicing is hard to predict in silico and is
difﬁcult to analyze experimentally, silent or intronic
SNPs that may cause a phenotype or a disease by chang-
ing splicing patterns are often not investigated (Pagani
and Baralle 2004). Thus, novel approaches are urgently
needed to identify splice-relevant SNPs.
Recently, we reported the widespread occurrence of
subtle alternative splice events that insert or delete the
sequence NAG (N denotes A, C, G, or T) in mRNA
(Hiller et al. 2004). This happens if both AG alleles of
a NAGNAG acceptor can be chosen by the spliceosome.
We termed the upstream acceptor in this tandem motif
the “E acceptor” and the downstream one the “I accep-
tor.” The products that arise from the use of E and I
acceptors are called “E and I transcripts and proteins,”
respectively. The consequences of NAG insertion/de-
letions (indels) in mRNAs for the respective protein se-
quences are highly diverse and comprise eight different
single–amino acid (aa) indel events, the exchange of a
dipeptide and an unrelated aa, or the creation/destruc-
tion of a stop codon. Tandem acceptors are conserved
292 The American Journal of Human Genetics Volume 78 February 2006 www.ajhg.org
Table 1
Correlation between Acceptor Genotypes and the Appearance of E and I Transcripts
dbSNP ID
GENE
SYMBOL
OBSERVATIONS FOR GENOTYPE
Homozygous NAGNAG Heterozygous Homozygous Non-NAGNAG
No. of Probands cDNA Transcripts No. of Probands cDNA Transcripts No. of Probands cDNA Transcript
rs2245425 TOR1AIP1a 3 EI 6 EI 2 I
rs2275992 ZFP91a 1 EI 7 EI 4 E
rs1558876 KIAA1001 0 … 6 EI 6 E
rs2290647 KIAA1533 0 … 4 EI 8 E
rs4590242 GABRR1 11 EI 1 EI 0 …
rs1152522 C14orf105 0 … 0 … 12 I
NOTE.—EI indicates presence of both E and I transcripts; E indicates only E transcripts; I indicates only I transcripts.
a See also ﬁgure 2.
between human and mouse, and the use of E or I accep-
tors can be controlled in a tissue-speciﬁc manner. Our
results concerning the frequency and tissue speciﬁcity
were conﬁrmed by others (Tadokoro et al. 2005). Fur-
thermore, E/I protein isoforms have functional differ-
ences (Condorelli et al. 1994; Tadokoro et al. 2005),
and the SNP rs1650232 within a NAGNAG acceptor is
associated with respiratory-distress syndrome (Karinch
et al. 1997).
Since NAGNAG acceptors occur in ∼30% of human
genes, we were interested in ﬁnding SNPs that may affect
this type of alternative splicing. By scanning the SNP an-
notation of the human reference sequence, we identiﬁed
those SNPs and provide experimental evidence of respec-
tive variations in the alternative splicing patterns. In ad-
dition, we introduce a classiﬁcation for NAGNAG ac-
ceptors, with respect to their splicing plausibility, to bring
forward a highly effective approach for predicting splice-
relevant SNPs.
Methods
Identiﬁcation of SNPs Affecting NAGNAG Acceptors
We downloaded the human genome assembly from the UCSC
Genome Browser (UCSCHuman Genome Browser, hg17,May
2004) as well as from RefSeq (refGene.txt.gz, January 12,
2005) and SNP annotations (snp.txt.gz, January 9, 2005).
From the transcripts, we extracted a list of unique genomic
positions of acceptor sites. We used the genomic position of
the acceptors to select those SNPs that overlap the ﬁrst 3 nt
of an exon or the last 6 nt of an intron. Then, we evaluated
whether one of both AG alleles or one of the two Ns in the
NAGNAG pattern is polymorphic. SNPs are the only type of
polymorphisms that were considered.
To check whether a tandem acceptor is EST conﬁrmed, we
used BLAST with a search string of 30 nt from the upstream
exon and 30 nt from the downstream exon—taking the non-
annotated acceptor into account—against the human fraction
of the dbEST database (December 2004) and against the mRNA
sequences downloaded from GenBank (December 2004). At
most, one mismatch or one gap was allowed.
Comparison with the Chimpanzee Genome
We downloaded the chimpanzee genome working draft as-
sembly from UCSC Genome Browser (UCSC Chimpanzee Ge-
nome Browser, panTro1, November 2003). We compared hu-
man polymorphic sites with the chimpanzee sequence, using
BLAST, with 101-nt queries consisting of one of the SNP al-
leles, as well as 50 nt upstream and 50 nt downstream. Only
hits with at least 95% identity and no other mismatch in the
5…5 context of the SNP were considered.
Null Model for Gain of NAGNAG Acceptors
Brieﬂy described, we determined the ancestral allele variant
for 2,439 SNPs that overlap an acceptor in the 9-nt context
by comparing the genomic sequence context with the chim-
panzee genome. In addition, we selected a set of 8,082 acceptor
sites not affected by known SNPs. Then, the 2,439 SNPs were
randomly assigned to one of those acceptors, given that the
ancestral allele variant is present at the respective position.
This position was replaced by the nonancestral allele, and we
evaluated and counted the possible impact on a NAGNAG
acceptor. More details are given in appendix A.
Experimental Veriﬁcation of Alternative Splicing
at Polymorphic NAGNAG Acceptors
Genomic DNA and cDNA from 12 whites were kindly pro-
vided by Gerd Birkenmeier (Leipzig) and were puriﬁed from
whole blood by standard methods. First-strand cDNA was
derived from oligo-dT primed reverse transcription.
For determination of the respective genotypes, ∼20 ng of
genomic DNA was used to PCR amplify the regions of the
respective SNP through use of Ready-To-Go PCRbeads (Amer-
sham). PCR conditions were 1 cycle of denaturation at 95C
for 30 s; followed by 38 cycles of denaturing at 92C for 30
s, annealing at 59C for 30 s, and extension at 72C for 60 s;
and 1 cycle of ﬁnal extension at 72C for 5 min. PCR products
were puriﬁed by precipitation and were sequenced with the
same primers used for PCR ampliﬁcation by the dye terminator
method by use of BigDye v3.1 (Applied Biosystems). To iden-
tify E and I transcripts, cDNA from the genotyped individuals
was ampliﬁed using the same PCR conditions with transcript-
speciﬁc primers.
For ampliﬁcation of genomic DNA and subsequent sequenc-
www.ajhg.org Hiller et al.: SNPs in NAGNAG Splice Acceptors 293
Figure 1 Schematic illustration of how SNPs affect splicing at
NAGNAG acceptors. A, SNP alleles at position 2, 1, 2, or 3
of a NAGNAG acceptor destroy this motif by affecting the E (left) or
I (right) acceptor, thus preventing alternative splicing. B, SNP alleles
at intron positions 5 and 4 can create a novel E acceptor (left)
and, at exon positions 2 and 3, a novel I acceptor (right), thus
yielding a NAGNAG motif. Acceptors at these alleles may allow al-
ternative splicing, as indicated by the two transcripts (E transcript
above; I transcript below). C, SNP alleles at position 3 or 1 of a
NAGNAG acceptor can convert a plausible NAGNAG that allows
alternative splicing (left) to an implausible one that allows only the
expression of one transcript (right), or vice versa. Positions refer to a
standard intron-exon boundary. H denotes A, C, or T; upper- and
lowercase letters indicate exonic and intronic nucleotides, respectively;
exonic nucleotides are boxed.
ing of the resulting amplicons that correspond to SNPs listed
in table 1, we used primers 5′-CAGCTACGGTTTGCTG-
AGAA-3′ and 5′-ACAGAGGGGACAGGGAGATT-3′ for ge-
notyping rs2245425, 5′-GATTTTCCTGGAGGAGAGGG-3′
and 5′-CAAGTTCAAAGCAAGCCTCC-3′ for rs1558876, 5′-
AGGAGGCGTGCTATCTGGTA-3′ and 5′-GTAGGAAGCC-
CTGGAGGAAG-3′ for rs2290647, 5′-GCCATTGAGTTG-
TCATCACC-3′ and 5′-ACCCATTAGCTTGGCAACAG-3′ for
rs2275992, 5′-AAGAATGGCGTCCATTTCAC-3′ and 5′-TTT-
CTGATCCTTGGTGAGGG-3′ for rs4590242, and 5′-CCTT-
CAACCTCAATGACGAAA-3′ and 5′-CACAAAGGACTTGT-
CAGGGA-3′ for rs1152522. RT-PCR for transcript ampliﬁ-
cation was done with primers 5′-GAAAGCGCGTACTAC-
CTTCG-3′ and 5′-AATCCCTGGATCTGGCCTTA-3′ for
TOR1AIP1, 5′-AGGCTACAACCACCCTCCTT-3′ and 5′-
ACTTCCCCCTTGACGAGTTT-3′ for KIAA1001, 5′-AGAG-
GAGGACAAGGAGGAGC-3′ and 5′-GAACAGCGTCTGTG-
TCTCCA-3′ for KIAA1533, 5′-GGACATCTGTTTCTCGC-
CAT-3′ and 5′-ATCCTTCCATCTCACAACGG-3′ for ZFP91
(GenBank accession number NM_170768), 5′-TCTTTCTTTT-
GTGGTGGGGA-3′ and 5′-TGTCAGGGACCCAGATCTTC-
3′ for GABRR1, and 5′-TGCAGGACCAGAATAAAGCC-3′
and 5′-TATGGTCCCTTGGACTTTGC-3′ for C14orf105. For
ZFP91 and TOR1AIP1, the amplicons obtained by RT-PCR
from individuals with each of the possible genotypes were
cloned into PCR2.1-TOPO (Invitrogen) and were propagated
in Escherichia coli TOP10 cells, respectively. Plasmids were
isolated from several isolated clones, and their inserts were
sequenced using plasmid primers. SNPs exhibiting nonances-
tral plausible NAGNAGs without EST evidence were selected
by high frequencies of the minor alleles rs1638152 (DTX2),
rs5248 (CMA1), and rs17105087 (SLC25A21). Genomic
primers used were for DTX2 (5′-TTTCCTCCTGGCAGCTT-
AGA-3′ and 5′-GCTGGGAGATGAAACCAAAG-3′), CMA1
(5′-GGCTCCAAGGGTGACTGTTA-3′ and 5′-CCCCACTTT-
CCCGTTTAACT-3′), and SCL25A21 (5′-AACTCCATGTCG-
TCCCAAAG-3′ and 5′-CAAAATCGTTTGTTCTTTGCC-3′).
Transcript-speciﬁc primers were used for DTX2 (5′-CAGG-
CATGACGAGTGTTCTG-3′ and 5′-CACAGCTAGGGACCC-
GAT-3′) and CMA1 (5′-CCCTGCTGCTCTTTCTCTTG-3′ and
5′-ACACACCTGTTCTTCCCCAG-3′).
Results
SNPs in NAGNAG Acceptors Inﬂuence Alternative
Splicing
We extracted from the UCSCHumanGenome Browser
(hg17, May 2004) all annotated SNPs that are located
within the last 6 nt of an intron or within the ﬁrst 3 nt
of an exon, given intron-exon boundaries from RefSeq
transcripts. From these SNPs, we selected those that affect
a NAGNAG acceptor. With respect to the human refer-
ence genome sequence, the alternative SNP allele can cre-
ate or destroy a NAGNAG acceptor by affecting one of
both AG alleles (ﬁg. 1A and 1B). Since the nucleotide
upstream of any acceptor AG is usually C or T (Stamm
et al. 2000) and a change at this position is likely to alter
alternative splicing at a tandem acceptor, we also consid-
ered SNPs at the N positions in an existing tandem (ﬁg.
1C). We found a total of 137 NAGNAG-affecting SNPs
(table 2). Aware of the uncertainty about the true nature
of SNPs in segmental duplications (Fredman et al. 2004;
Taudien et al. 2004), we excluded seven (5%) of the
variations from further analysis. Our precaution was
justiﬁed by genotyping SNP rs1638152 in 12 whites; we
consistently found both alleles and both transcripts
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Table 2
SNPs That Affect NAGNAG Acceptors
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 3
Phase Distribution of Human Introns and NAGNAG Acceptors
INTRON CLASS
NO. (%) OF INTRONS BY PHASE
0 1 2
Conﬁrmed NAGNAGsa,b 349 (39.8) 379 (43.2) 150 (17.0)
Plausible NAGNAGsb 1,111 (42.5) 1,099 (42.0) 405 (15.5)
Implausible NAGNAGsb 2,568 (54.5) 1,466 (31.1) 677 (14.4)
All intronsc (46) (33) (21)
NOTE.—Only NAGNAGs that are located upstream of a coding
exon are considered.
a EST/mRNA conﬁrmed.
b From table 1 of Hiller et al. (2004).
c Genomewide frequencies (Long and Deutsch 1999).
(DTX2 [GenBank accession numbers DQ082728 and
DQ082730]), which is a strong indication for paralo-
gous sequence variants and/or multisite variations (com-
binatorial ). Since dbSNP entries sometimesPp .0003
are the result of sequencing errors, we manually ex-
amined the trace data (if available) and excluded a fur-
ther nine SNPs (7%). Thus, we considered a total of 121
bona ﬁde SNPs affecting NAGNAG acceptors.
Searching dbEST (December 2004), we obtained con-
ﬁrmation for alternative splicing at 16% (19 of 121) of
these tandem acceptors. However, this percentage must
be considered a lower bound. In addition to the general
limitations of an EST-based evaluation of alternative
splicing (insufﬁcient EST coverage, especially for tandem
acceptors that are spliced in a tissue-speciﬁc manner),
the allele frequencies of the NAGNAG alleles and popu-
lational biases in EST sampling introduce further con-
strictions. Noteworthy, 18 (95%) of the 19 conﬁrmed
tandem acceptors match the consensus HAGHAG (H
denotes A, C, or T). Thus, 26% of the 68 polymorphic
HAGHAGs are EST conﬁrmed, whereas only 1.9% of
the 53 acceptors carrying G at one or both variable po-
sitions of the NAGNAG motif are EST supported. This
is in line with our previous genomewide analysis, in
which 31% of the HAGHAGs and only 1.7% of the
remaining NAGNAGs were found to be experimentally
conﬁrmed (see table 1 of Hiller et al. [2004]). On the
basis of these differences in the degree of conﬁrma-
tion by mRNA and EST data, we propose to subdivide
all tandem acceptors into “plausible” (HAGHAG) and
“implausible” (GAGHAG, HAGGAG, or GAGGAG)
acceptors. Further support for this classiﬁcation comes
from the genomewide observation that all plausible
NAGNAGs have the same bias toward intron phase 1,
as described elsewhere (Hiller et al. 2004) for experimen-
tally conﬁrmed NAGNAGs, whereas the introns with im-
plausible tandem acceptors are not biased toward phase
1 (table 3).
Accordingly, 68 (56%) of the 121 SNPs affect a plau-
sible NAGNAG. However, four of those convert a plau-
sible into another plausible NAGNAG, which has pre-
sumably no drastic consequence for NAGNAG splicing,
even though we cannot exclude the possibility of changes
in the ratio of E to I transcripts or of changes in tissue
speciﬁcity. Thus, we consider the remaining 64 (53%)
SNPs as relevant for NAGNAG splicing (table 4).
Cases of SNPs that comprise NAGNAG-acceptor and
non-NAGNAG–acceptor alleles represent knockout ex-
periments made by nature. We took this opportunity to
investigate the assumed correlation between NAGNAG-
acceptor genotypes and the appearance of E and I tran-
scripts. Such a study seemed reasonable, since, so far,
it has been performed in artiﬁcial splicing systems only
(Tadokoro et al. 2005). We selected six SNPs with a
heterozygosity of 10.2 that affect EST-conﬁrmed HAG-
HAG acceptors for genotyping and detection of tran-
script forms. In two cases, we did not ﬁnd either geno-
types with at least one NAGNAG allele or genotypes
that are homozygous for the non-NAGNAG allele. In
the remaining four cases, we consistently observed E and
I transcripts in cells with at least one HAGHAG allele,
whereas cells that do not have a HAGHAG acceptor
allele produced only one transcript (table 1). This strict
correlation between NAGNAG alleles and alternative
splicing is illustrated for ZFP91 and TOR1AIP1 in ﬁg-
ure 2. These results conﬁrm that NAGNAG motifs are
necessary for this type of alternative splicing.
Next, we asked whether NAGNAG motifs created by
the nonancestral SNP alleles are also sufﬁcient for alter-
native splicing. With regard to the human reference se-
quence, in 36 (56%) of 64 cases, a novel NAGNAG is
created; in 18 (28%), a known NAGNAG is destroyed
by affecting an AG; and in 10 (16%), the N positions
are changed. Since the appearance of a SNP allele in the
current human genome build is rather random and does
not reﬂect either the relative allele frequency in a deﬁned
population or its evolutionary history, the best reference
for the question of gain versus loss of NAGNAG accep-
tors is the UCSC Chimpanzee Genome Browser (pan-
Tro1, November 2003). When the sequence context of
the 64 plausible NAGNAG-affecting SNPs is compared,
for 61 (95%), the orthologous chimpanzee nucleotide is
identical to one of both human alleles, which we there-
fore consider the ancestral one (Watanabe et al. 2004).
In 43 cases, the plausible NAGNAG is gained (nonan-
cestral), and, in 18 cases, it is lost (ancestral). Consistent
with our assumption that novel plausible NAGNAGs
are very likely functional, we found EST evidence of
alternative splicing in 16% (7 of 43) (table 4). To pro-
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Figure 2 SNPs that affect plausible NAGNAG acceptors as knockout experiments made by nature. A, Schematic representation of the
nomenclature of NAGNAG acceptors (left) and transcripts (right). B, SNP rs2245425 affecting the E acceptor of TOR1AIP1 exon 3 leads to
the exclusive expression of the I transcript from the A allele (NAGNAG position 4; for numbering scheme, refer to ﬁg. 1). C, SNP rs2275992
affecting the I acceptor of ZFP91 exon 5 leads to the exclusive expression of the E transcript from the G allele (position 2). Homozygous
NAGNAG allele (a), heterozygous (b), and homozygous non-NAGNAG allele (c) are shown as genomic with genotypes (left); cDNA with E:
I transcript ratio determined by counting subcloned and sequenced RT-PCR fragments (right). The asterisk (*) denotes E transcripts that can
be assigned to the SNP alleles in the I acceptor ( ; ).Ap 15 Gp 72
vide further experimental support that respective SNP
alleles enable alternative NAGNAG splicing, we selected
two nonancestral plausible NAGNAGswithout EST evi-
dence. As expected, in leukocytes of individuals hetero-
zygous or homozygous for the respective tandem allele
of rs5248, we observed the expression of E and I tran-
scripts (GenBank accession numbers DQ082727 and
DQ082729) in the ratios 4:14 and 11:7, respectively
(table 4). In the case of rs17105087, we were unable to
identify the nonancestral allele in our white population
sample. By analyzing the human-chimpanzee genomic
sequence context of the eight conﬁrmed nonancestral
NAGNAG alleles, we found three cases in which both
genomes are identical in a long range (rs2287800 [140/
123 identical nucleotides], rs3765018 [130/95 nt],
and rs2290647 [105/70 nt]). Since most splice en-
hancers function only within a distance of !100 nt from
the affected splice site (Schaal and Maniatis 1999), these
ﬁndings suggest that NAGNAG motifs are sufﬁcient for
alternative splicing in the context of a previously non-
NAGNAG acceptor.
Evolutionary Aspects of SNPs in NAGNAG Acceptors
At ﬁrst glance, surprisingly, the large majority (43
[70%] of 61) of the plausible NAGNAGs are created
(35 novel tandem AG alleles and 8 conversions of im-
plausible into plausible), whereas only 18 are destroyed
(16 AG destructions and 2 conversions of plausible into
implausible). Therefore, we questioned whether there is
a trend toward gain-of-NAGNAG acceptors in the hu-
man lineage. To test this, we used a null model that maps
SNPs to randomly chosen acceptors (see appendix A)
and found nearly the same relation for gain and loss of
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Table 5
Intron Phase Distribution and Single aa Events of Nonancestral Plausible NAGNAG Acceptors
NO. (%) OF INTRONS BY PHASE
NO. (%) OF
SINGLE-AA EVENTS,
PHASES 1 AND 2ACCEPTOR 0 1 2
Nonancestral NAGNAG allelesa 12 (31.6) 16 (42.1) 10 (26.3) 24 (92.3)
Nonpolymorphic conﬁrmed NAGNAGsb 349 (39.8) 379 (43.2) 150 (17.0) 487 (92.1)
NOTE.—Only NAGNAGs that are located upstream of a coding exon are considered.
a Plausible polymorphic NAGNAGs for which the chimpanzee acceptor has no NAGNAG.
b EST/mRNA-conﬁrmed NAGNAGs (Hiller et al. 2004).
plausible NAGNAG acceptors. Thus, the high number
of nonancestral plausible NAGNAGs is presumably a
consequence of the fact that NAGNAG motifs represent
only 5% of all human acceptors (Hiller et al. 2004). In
consequence, in recent primate genomes, a constant bias
seems to exist toward the accumulation of NAGNAG
acceptors, which leads to an increased complexity of the
transcriptome and proteome, antagonized by purifying
selection. The question of whether the currently observed
NAGNAG fraction among human acceptors represents
the saturation level has to be addressed by further com-
parative genomewide analyses.
Furthermore, we observed striking differences in the
numbers of SNPs that affect the AG of the E or I acceptor
in ancestral plausible and implausible NAGNAGs, re-
spectively. For the 16 ancestral plausible HAGHAGs, the
E acceptor is affected in 11 cases and the I acceptor in
5. In contrast, for 22 implausible HAGGAGs (one an-
cestral GAGGAG and two GAGHAGs were omitted),
we found 5 and 17 cases, respectively (Fisher’s exact test
). Interestingly, we observed the same trendPp .00766
by comparing all 138 human NAGNAGs that are not
conserved in the chimpanzee genome (one GAGGAG
and seven GAGHAGs were omitted). The I acceptors of
79 HAGHAGs are affected in 56% (44), whereas the
GAG of 59 HAGGAGs is affected in 83% (49) (Fisher’s
exact test ). Implausible GAGGAG andGAG-Pp .0009
HAG motifs were not considered, since the number of
cases is too small.
Since tandem acceptors are nonrandomly distributed
in the human genome, with a bias toward intron phase
1 and toward single-aa indels in phase 1 and 2, we ques-
tioned whether the nonancestral plausible NAGNAGs
are also biased. Indeed, these NAGNAGs show the same
bias toward intron phase 1, and they also have a strong
tendency to result in single-aa indels (table 5). Thus, the
process of establishing SNPs that are relevant for alter-
native NAGNAG splicing in the human population seems
to be a nonrandom process that is subject to the same
evolutionary forces as the maintenance of the tandem
acceptors themselves.
Discussion
Since splicing variations are coming more and more into
the research focus of human molecular genetics (Lopez-
Bigas et al. 2005), novel approaches are needed to iden-
tify splice-relevant SNPs. By data mining the SNP anno-
tation of the UCSC Human Genome Browser, we iden-
tiﬁed 121 variations that may affect alternative splicing
by creation, destruction, or changing of NAGNAG ac-
ceptors. To improve the speciﬁcity of our prediction, we
classiﬁed NAGNAG acceptors into “plausible” (HAG-
HAG) and “implausible” (GAGHAG, HAGGAG, or
GAGGAG) ones. This subdivision of the tandem accep-
tors, primarily based on the degree of conﬁrmation by
mRNA and EST data, is further supported by (1) the fact
that GAG acceptors are very rare (Stamm et al. 2000),
(2) our genomewide observation that only plausible and
not implausible NAGNAGs have the same bias toward
intron phase 1 as experimentally conﬁrmed NAGNAGs
(Hiller et al. 2004), and (3) the observed differences in
the numbers of SNPs that affect the AG of the E or I
acceptor in ancestral plausible and implausible NAG-
NAGs, respectively. The last indicates that the selection
pressure to maintain the E acceptor for HAGGAGs is
higher than the pressure to preserve the coding sequence,
since destruction of the HAG acceptor will leave a GAG
that is unlikely to act as an acceptor site. In contrast,
for plausible HAGHAGs, destruction of either AG is
much less deleterious, since the other will still function
as an acceptor. Thus, the identiﬁed 64 SNPs in plausible
NAGNAGs are highly predictive of variations in alter-
native splicing. Nevertheless, it represents an experi-
mental and bioinformatic challenge for future research
to elucidate what makes the rare cases of conﬁrmed im-
plausible NAGNAG acceptors.
Although it seems obvious that the disruption of a
plausible NAGNAG acceptor abolishes the formation of
alternative transcripts, SNPs in these motifs provide us
with unique knockout experiments by nature to conﬁrm
this hypothesis experimentally. Analyzing the expression
of E and I transcripts in cells with at least oneHAGHAG
allele or without HAGHAG alleles, we have shown that
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Figure 3 SNP affecting the I acceptor and the aa sequence of the E protein (rs2275992 in ZFP91). Homozygosity of the G allele without
a NAGNAG results in the expression of one protein (A), homozygosity of the A allele with the NAGNAG results in two (B), and heterozygosity
results in three isoforms (C). All three transcripts are conﬁrmed by at least four ESTs/mRNAs. The two allele variants are highlighted in light
and dark gray. Amino acids are shown below the second codon position. Upper- and lowercase letters indicate exonic and intronic nucleotides,
respectively. Exons are boxed.
Table 6
Human Disease Genes with SNPs Affecting Plausible NAGNAG Acceptors
dbSNP ID Gene Symbol RefSeq ID Disease MIM Number(s) PubMed ID(s)
rs3020724 CYP17A1 NM_000102 Adrenal hyperplasia, congenital #202110, *609300 4303304
rs12042060 FIBL-6 NM_031935 Age-related macular degeneration #603075, *608548 14570714
rs2243187 IL19 NM_153758 Asthma *605687 15557163
rs8176139 BRCA1 NM_007304 Breast cancer *113705, #114480 9167459
rs11567804 C3AR1 NM_004054 Bronchial asthma *605246 15278436
rs3025420 DBH NM_000787 Congenital dopamine-beta-hydroxylase deﬁciency #223360, *609312 14991826
rs2409496 GART NM_175085 Down syndrome *138440 9328467
rs1804783 CACNA1A NM_023035 Episodic ataxia-2, familial hemiplegic migraine, spinocerebellar
ataxia-6, idiopathic generalized epilepsy #183086, #141500, #108500, *601011 8988170, 8898206, 9302278
rs2010657 GGT1 NM_013421 Glutathionuria 231950 238530, 7623451
rs2307130 AGL NM_000644 Glycogen storage disease type III 232400 9032647, 10925384
rs1833783 FTL NM_000146 Hyperferritinemia-cataract syndrome #600886, *134790 7493028, 12199804
rs11661706 EPB41L3 NM_012307 Meningioma, lung cancer *605331 10888600, 9892180
rs2275992 ZFP91 NM_170768 Acute myeloid leukemia #601626 12738986,
rs1071716 TPM2 NM_213674 Nemaline myopathy-4, distal arthrogryposis 1 #609285, #108120, *190990 11738357, 12592607
rs2521612 SLC4A1 NM_000342 Renal tubular acidosis, ovalocytosis, spherocytosis #179800, 166900, 109270 9600966, 1737855, 9973643
rs9644946 GOLGA1 NM_002077 Sjogren syndrome 270150, *602502 9324025
rs17173698 PAPSS2 NM_004670 Spondyloepimetaphyseal dysplasia *603005 9714015
rs9606756 TCN2 NM_000355 Transcobalamin II deﬁciency 275350 14632784
rs7862221 TSC1 NM_000368 Tuberous sclerosis #191100, *605284 12773162, 14551205
rs11574323 WRN NM_000553 Werner syndrome #277700, *604611 9012406, 8968742
the NAGNAG motif is necessary for this type of al-
ternative splicing. In a subsequent analysis, we asked
whether NAGNAG motifs created by the nonancestral
SNP alleles allow alternative splicing. Usually, the intro-
duction of an AG anywhere in the pre-mRNA does not
create a functional acceptor site, since a polypyrimidine
tract upstream and possibly enhancer sequences are re-
quired for recognition by the spliceosome. However, we
suppose that the creation of a second AG 3 bases up or
downstream of an existing acceptor is very likely to re-
sult in a functional tandem acceptor, since the splice-
relevant sequence context is already present.
Referring to the chimpanzee genome as the reference
for ancestral SNP alleles, we found EST and RT-PCR
evidence that novel plausible NAGNAGs are most likely
functional. This implies that a change of a normal ac-
ceptor to a plausible NAGNAG acceptor by a single
mutation is sufﬁcient to enable alternative splicing. Al-
though the mechanism of NAGNAG splicing is not un-
derstood in detail, our ﬁndings argue against a general
involvement of signals other than the NAGNAG itself.
Thus, we conclude that SNPs in plausible NAGNAGs
have an inﬂuence on NAGNAG splicing, regardless of
whether the NAGNAG is ancestral. However, additional
signals might be necessary for regulation of alternative
splicing at tandem receptors.
Most interestingly, 23% (15 of 64) of SNPs in plau-
sible NAGNAGs are translationally nonsilent and, thus,
introduce a novel dimension of variability on the protein
level by changing the I acceptor and the aa sequence of
the E protein. Whereas homozygotes express either one
or two isoforms, heterozygosity results in three different
proteins (ﬁg. 3). As listed in the Human Gene Mutation
Database, the aa change can be dramatic—for example,
as from Glu to the oppositely charged Lys in PAPSS2
(rs17173698), which leads to a decrease in immuno-
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reactive protein (Xu et al. 2002). However, the third iso-
form of the protein generated by alternative NAGNAG
splicing had not been taken into consideration. More-
over, it is conceivable that some of the SNPs in NAG-
NAG acceptors that allow the formation of three pro-
tein isoforms in heterozygotes may confer a heterozy-
gous advantage.
Alternative splicing at tandem acceptors can result in
the gain/loss of a premature stop codon in the mRNA.
Among SNPs affecting plausible NAGNAGs, the G al-
lele of SNP rs9644946 changes the acceptor context of
GOLGA1 exon 8 from AAATAG to AAGTAG. Since
intron 7 resides in phase 0, an inframe TAG insertion
would be the consequence if the novel E acceptor is used.
Interestingly, the gene codes for an autoantigen associ-
ated with Sjogren syndrome (MIM 270150). Since the
E acceptor is preferred in alternative NAGNAG splicing
(Hiller et al. 2004), the novel AAG acceptor is likely to
be functional. The resulting E transcript is a candidate
for nonsense-mediated mRNA decay (Maquat 2004).
Thus, the AAGTAG allele would result in a lower pro-
tein expression. Alternatively, it is possible that the
mRNA containing the premature stop codon escapes
degradation, and the truncated protein may exhibit au-
toantigenic properties. It remains to be elucidated in
populations with a sufﬁciently high allele frequency (e.g.,
0.099 in the PERLEGEN panel that contains 24 samples
of Chinese descent), regardless of whether alternative
splicing at the AAGTAG acceptor contributes to the
disease.
A second example of potential disease relevance is the
SNP rs363209, the G allele of which creates a novel plau-
sible AAGCAG acceptor of intron 6 in APPBP1 (Gen-
Bank accession number NM_003905). The APP-BP1
protein binds to the carboxyl-terminal region of the
amyloid precursor protein (APP) and interacts with the
ubiquitin-activating enzyme E1C (UBE1C [homolog to
yeast Uba3]) in the process of neddylation (Walden et
al. 2003). APP plays a central role in Alzheimer disease
and Down syndrome. Dysfunction of the APP-BP1 in-
teraction with APP has been suggested to be one cause
of Alzheimer disease (Chen 2004). The protein-protein
interactions of the APP-BP1 E and I isoforms may be
different andmodulate the respective processes. It should
be mentioned that the UBE1C gene (GenBank accession
number NM_003968) itself contains a tandem acceptor
(CAGAAG in front of exon 11). This may further in-
crease the ﬂexibility of the neddylation process by all
four combinations of the E/I protein isoforms from two
genes each.
The disease relevance of a NAGNAG SNP is dem-
onstrated for the ABCA4 gene (Maugeri et al. 1999).
Maugeri et al. (1999) describe a NAGNAG muta-
tion (2588GrC, changing the acceptor site TAGGAGr
TAGCAG) that has a much higher frequency in patients
with Stargardt disease 1 (STGD1 [MIM 248200]) and
that is assumed to be a mild mutation that causes STGD1
in combination with a severe ABCA4 mutation. By ex-
perimental analysis of the splice patterns of two patients
with STGD1 who carry the mutation and one control
individual, they found that only the alleles with the TA-
GCAG produce two splice forms. Our study exactly pre-
dicts this mutation outcome.
In general, most of the SNPs that are described in
the present study—in particular, these in plausibleNAG-
NAGs—affect the E:I transcript ratio, depending on the
cell’s genotype. SNP alleles with a destroyed E acceptor
cause the exclusive expression of the I transcript. Alleles
that destroy an I acceptor result in an exclusive expres-
sion of the longer E transcript. SNPs that comprise a
plausible and an implausible NAGNAG allele will se-
riously hamper or disable splicing at the GAG acceptor.
It has already been shown that a change in the ratio of
alternative splice forms can cause diseases. For example,
the change in the ratio of the alternative MAPT tran-
scripts containing three or four microtubule-binding re-
peats may be causal for frontotemporal dementia (MIM
600274) (Spillantini et al. 1998). Another example is the
WT1 gene, in which alternative donor usage results in
two protein isoforms that differ in 3 aa (KTS/KTS
isoforms) and function (Englert et al. 1995). The altered
ratio of KTS/KTS leads to Frasier syndrome (MIM
136680) (Barbaux et al. 1997). This situation is similar
to that of NAGNAG acceptors, since E/I protein iso-
forms are observed that have functional differences (Con-
dorelli et al. 1994; Tadokoro et al. 2005).
Altogether, 28% (18 of 64) of the plausibleNAGNAG
SNPs occur in known disease genes (table 6). Thus, they
are preferable candidates for more-detailed functional
analysis and association studies to link alternative splic-
ing with diseases. Currently, there are no general meth-
ods that allow the prediction of splice-relevant SNPs.
Focusing on SNPs that affect NAGNAG acceptors, we
present a highly effective approach for the identiﬁcation
of SNPs that result in variations in alternative splicing
patterns.
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Appendix A
Randomization Null Model for NAGNAG SNPs
To assess whether there is a preference for creating
plausible NAGNAGs, we used a simulation that assigns
a new acceptor to the 2.896 SNPs that overlap an ac-
ceptor in the 9-nt context and evaluates a possible NAG-
NAG-relevant outcome. For the 2,896 SNPs, we blasted
the 101-nt genomic context (50 nt upstream and 50 nt
downstream of the SNP) against the chimpanzee genome
to determine the ancestral allele variant. We kept align-
ments with at least 95% identity and no mismatches in
a 5-nt context around the SNP position. This yielded
a total of 2,439 SNPs. Then, we blasted the 103-nt con-
texts (50 nt up- and downstream of the acceptor NAG)
of 10,000 human acceptor sites (excluding the acceptors
that are overlapped by a known SNP) against the chim-
panzee genome and kept 8,082 for which we found an
alignment (95% identity and nomismatch10nt around
the NAG). Then, we assigned a new acceptor (randomly
chosen from the 8,082) to a given SNP. We chose an
acceptor with the ancestral allele variant at the respective
position (e.g., if a SNP changes a CrG at position 4 of
the 9-nt context, the new acceptor must also have a C
at position 4). Since a methylated C in a CG context
frequently mutates to a T, we assigned a new acceptor
with the same sequence context at this position if the
SNP represents a CrT mutation in a CG context (or a
GrA mutation in a GC context on the opposite strand).
This assures that context-dependent mutations are sim-
ulated in the same context. If a new acceptor is assigned
to a SNP, we evaluated the possible impact on a NAG-
NAG acceptor. For each of the 2,439 SNPs, we succes-
sively assigned 10 randomly chosen acceptors (avoiding
duplicate assignments).
The whole procedure was repeated 10 times, with dif-
ferent starts of the random-number generator. We calcu-
lated the following statistics from the 10 runs: (1) mini-
mum and maximum percentage of creation versus de-
struction of a plausible NAGNAG, (2) minimum and
maximum percentage of changes from a plausible to an
implausible NAGNAG versus changes from an implau-
sible to a plausible NAGNAG, and (3) minimum and
maximum percentage of “gain of plausible NAGNAG”
versus “loss of plausible NAGNAG.” “Gain of plausible
NAGNAG” is the sum of created, plausible NAGNAGs
and changes from implausible to plausible. “Loss of
plausible NAGNAG” is the sum of destroyed, plausible
NAGNAGs and changes from plausible to implausible.
These values were compared with the observed values
by Fisher’s exact test. For (1), we obtained P values
between .52 and .75, for (2), P values between .72 and
1, and, for (3), P values between .66 and .88. Thus, the
observed bias toward “gain of plausible NAGNAG” is
comparable to the expectation.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
dbEST, ftp://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/est_human.gz (for
the human portion of dbEST)
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for the human
mRNA download, ZFP91 [accession number NM_170768],DTX2
[accession numbers DQ082728 and DQ082730], CMA1 [accession
numbers DQ082727 and DQ082729]), APPBP1 [accession number
NM_003905], and UBE1C [accession number NM_003968])
Human Gene Mutation Database, http://www.uwcm.ac.uk/uwcm/mg/
hgmd0.html
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.gov/Omim/ (for Sjogren syndrome, STGD1, frontotemporal demen-
tia, and Frasier syndrome)
UCSC Chimpanzee Genome Browser, http://hgdownload.cse.ucsc.edu/
goldenPath/PANTro1/bigZips/ (for source download panTro1 [No-
vember 2003])
UCSC Human Genome Browser, http://hgdownload.cse.ucsc.edu/
goldenPath/hg17/bigZips/ (for source download hg17)
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